Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that will make the kidney disease drug developer the first U.S. biotech ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

If you’re in a calorie deficit – either from dieting or while taking a weight loss drug – these exercises help direct your ...

CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...

Beta Bionics hit net sales of $44.7m in the first nine months of 2024, marking an increase from $3.6m in 2023. Beta Bionics’ ...

Metastatic breast cancer and breast cancer treatment can cause symptoms that produce appetite loss, but there are strategies to help. Here are the top tips.

IPO content provided by Renaissance Capital LLC, manager of the IPO-focused ETFs (tickers: IPO, IPOs).